- Soligenix reports clinical update centered on cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma that primarily affects the skin.
- The interim update highlighted that the overall blinded aggregate response rate observed in patients who have completed treatment remains consistent with prior reporting.
- In addition, the company reported positive results from a study evaluating HyBryte(TM) against Valchlor(R), an existing treatment option for cutaneous T-cell lymphoma.
Advancing clinical research while generating positive data is a critical combination in biotechnology, particularly when addressing diseases with limited treatment options. Soligenix (NASDAQ: SNGX) is demonstrating that momentum as it provides both an encouraging clinical update from its phase 3 FLASH2 study and positive comparative clinical results for its HyBryte therapy, reinforcing the company’s focus on developing innovative treatments for serious conditions.
Questions around this news
What did Soligenix report about its FLASH2 study?
The release describes an interim update from the phase 3 FLASH2 study in cutaneous T-cell lymphoma. It says the overall blinded aggregate response rate among patients who had completed treatment remained consistent with prior reporting. The release does not provide a numerical response rate or further details about the interim analysis.
What did the comparative study evaluate?
The release reports positive results from a study evaluating HyBryte against Valchlor, which it describes as an existing treatment option for cutaneous T-cell lymphoma. It does not provide study methods, numerical results, or further detail on how the treatments compared, so those specifics cannot be established from this announcement.
What does a blinded aggregate response rate mean in a clinical study?
A response rate is the proportion of participants who meet a study’s criteria for a treatment response. An aggregate rate combines responses across a defined group of participants. In a blinded study, participants, researchers, or both may not know which treatment an individual receives, helping limit bias in study conduct or assessment.
The research highlighted in these announcements centers on cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma that primarily affects the skin. According to the National Cancer Institute, CTCL can cause persistent skin lesions, plaques and tumors, often leading to significant…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
At a glance
- Company
- Soligenix
- Ticker
- NASDAQ: SNGX
Products and programs
SEC filings
Earlier from Soligenix
- Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy
- Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results
- Soligenix (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease
- Soligenix (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach
- Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
